CO5150193A1 - OPEN DIHYDROXIACIDE AND INHIBITORS SALTS OF HMG-CoA REDUCTASA - Google Patents
OPEN DIHYDROXIACIDE AND INHIBITORS SALTS OF HMG-CoA REDUCTASAInfo
- Publication number
- CO5150193A1 CO5150193A1 CO00016008A CO00016008A CO5150193A1 CO 5150193 A1 CO5150193 A1 CO 5150193A1 CO 00016008 A CO00016008 A CO 00016008A CO 00016008 A CO00016008 A CO 00016008A CO 5150193 A1 CO5150193 A1 CO 5150193A1
- Authority
- CO
- Colombia
- Prior art keywords
- open
- dihydroxiacide
- hmg
- inhibitors
- salts
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Una composición farmacéutica oral que comprende una cantidad terapéuticamente eficaz de un compuesto seleccionado entre una estatina en su forma de dihidroxiácido abierto y una sal ó éster farmacéuticamente aceptables de ésta junto con un vehículo portador farmacéuticamente aceptable, composición farmacéutica formulada en una forma de dosificación de liberación retardada en donde la liberación sustancial del compuesto a partir de la forma de dosificación a un paciente se retarda hasta después del paso de la forma de dosificación a través del estómago.<EMI FILE="00016008_1" ID="1" IMF=JPEG >An oral pharmaceutical composition comprising a therapeutically effective amount of a compound selected from a statin in the form of an open dihydroxy acid and a pharmaceutically acceptable salt or ester thereof together with a pharmaceutically acceptable carrier vehicle, pharmaceutical composition formulated in a release dosage form delayed where substantial release of the compound from the dosage form to a patient is delayed until after the passage of the dosage form through the stomach. <EMI FILE = "00016008_1" ID = "1" MFI = JPEG>
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12322799P | 1999-03-08 | 1999-03-08 | |
| US26474499A | 1999-03-09 | 1999-03-09 | |
| PCT/US2000/002626 WO2000053173A1 (en) | 1999-03-08 | 2000-02-02 | Dihydroxy open-acid and salts of hmg-co-a reductase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5150193A1 true CO5150193A1 (en) | 2002-04-29 |
Family
ID=26821357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO00016008A CO5150193A1 (en) | 1999-03-08 | 2000-03-06 | OPEN DIHYDROXIACIDE AND INHIBITORS SALTS OF HMG-CoA REDUCTASA |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1161236A1 (en) |
| JP (2) | JP2002538202A (en) |
| AR (1) | AR022856A1 (en) |
| AU (1) | AU2866400A (en) |
| CA (1) | CA2364253A1 (en) |
| CO (1) | CO5150193A1 (en) |
| PE (1) | PE20001559A1 (en) |
| SV (1) | SV2002000036A (en) |
| WO (1) | WO2000053173A1 (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003523948A (en) * | 1999-11-04 | 2003-08-12 | アンドルクス コーポレーション | Treatment of amyloid β precursor disorder |
| AU2001288724A1 (en) * | 2000-09-06 | 2002-03-22 | Merck & Co., Inc. | Dihydroxy open-acid salt of simvastatin |
| SK4112003A3 (en) * | 2000-10-12 | 2004-01-08 | Nissan Chemical Ind Ltd | Preventives and remedies for complications of diabetes |
| IL160077A0 (en) * | 2001-08-16 | 2004-06-20 | Teva Pharma | Processes for preparing calcium salt forms of statins |
| KR20040026705A (en) | 2001-08-16 | 2004-03-31 | 테바 파마슈티컬 인더스트리즈 리미티드 | Processes for preparing calcium salt forms of statins |
| CN1612747A (en) * | 2002-01-09 | 2005-05-04 | 克鲁塞尔荷兰公司 | Use of red blood cell generation promoter in prevention and treatment of heart faiture |
| TW200404544A (en) * | 2002-06-17 | 2004-04-01 | Kowa Co | Controlled release pharmaceutical composition |
| AR040588A1 (en) | 2002-07-26 | 2005-04-13 | Schering Corp | PHARMACEUTICAL FORMULATION INCLUDING AN INHIBITOR OF CHOLESTEROL ABSORPTION AND AN INHIBITOR OF A HMGCO TO REDUCTASE |
| US8987322B2 (en) * | 2003-11-04 | 2015-03-24 | Circ Pharma Research And Development Limited | Pharmaceutical formulations for carrier-mediated transport statins and uses thereof |
| ATE428411T1 (en) * | 2003-11-07 | 2009-05-15 | Jj Pharma Inc | HDL-BOOSTING COMBINATION THERAPY COMPLEXES |
| US10208351B2 (en) | 2013-10-18 | 2019-02-19 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | RNY-derived small RNAs as biomarkers for atherosclerosis-related disorders |
| KR20190142406A (en) * | 2017-05-15 | 2019-12-26 | 유니버시티 오브 신시내티 | Compositions and methods for treating defects of avascular cartilage tissue by direct administration of one or more metabolites of simvastatin |
| CN113134086B (en) * | 2020-01-20 | 2024-05-24 | 深圳市长卿医学研究院 | Pharmaceutical composition for reducing blood fat |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225202A (en) * | 1991-09-30 | 1993-07-06 | E. R. Squibb & Sons, Inc. | Enteric coated pharmaceutical compositions |
| HU9203780D0 (en) * | 1991-12-12 | 1993-03-29 | Sandoz Ag | Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them |
| PL186907B1 (en) * | 1995-12-22 | 2004-03-31 | Kowa Co | Pharmaceutic composition stabilised by means of a basic substance |
| US5916595A (en) * | 1997-12-12 | 1999-06-29 | Andrx Pharmaceutials, Inc. | HMG co-reductase inhibitor |
-
2000
- 2000-02-02 WO PCT/US2000/002626 patent/WO2000053173A1/en not_active Application Discontinuation
- 2000-02-02 JP JP2000603662A patent/JP2002538202A/en not_active Withdrawn
- 2000-02-02 AU AU28664/00A patent/AU2866400A/en not_active Abandoned
- 2000-02-02 CA CA002364253A patent/CA2364253A1/en not_active Abandoned
- 2000-02-02 EP EP00907111A patent/EP1161236A1/en not_active Withdrawn
- 2000-03-06 CO CO00016008A patent/CO5150193A1/en unknown
- 2000-03-07 JP JP2000062746A patent/JP2000256191A/en active Pending
- 2000-03-07 PE PE2000000201A patent/PE20001559A1/en not_active Application Discontinuation
- 2000-03-07 AR ARP000101006A patent/AR022856A1/en unknown
- 2000-03-08 SV SV2000000036A patent/SV2002000036A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2866400A (en) | 2000-09-28 |
| PE20001559A1 (en) | 2001-01-16 |
| AR022856A1 (en) | 2002-09-04 |
| EP1161236A1 (en) | 2001-12-12 |
| CA2364253A1 (en) | 2000-09-14 |
| SV2002000036A (en) | 2002-02-05 |
| JP2002538202A (en) | 2002-11-12 |
| WO2000053173A1 (en) | 2000-09-14 |
| JP2000256191A (en) | 2000-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5150193A1 (en) | OPEN DIHYDROXIACIDE AND INHIBITORS SALTS OF HMG-CoA REDUCTASA | |
| CO5160329A1 (en) | METHOD FOR PROVIDING INCREASED ABSORPTION OF A PHARMACEUTICALLY ACCEPTABLE AMINA IN THE BLOOD OF A HUMAN AND COMPOSITION THAT INCLUDES A PHARMACEUTICALLY AMINE A NON-STEROID ANTI-INFLAMMATORY PHARMACO | |
| AR064895A2 (en) | PHARMACEUTICAL COMPOSITION ANHIDRA FOR THE TREATMENT OF HISTAMINE INDUCED DISORDERS | |
| CO5690131A1 (en) | DERIVATIVES OF ETER BIARILICO PRESENTING ACTIVITY AS INHIBITORS OF THE RECOVERY OF MONOAMINS FOR THE TREATMENT OF CNS DISORDERS | |
| CO5271657A1 (en) | DERIVATIVES OF AZAINDOL | |
| CO5570109A1 (en) | HETEROCICLIC DIHYDROPIRIMIDINE COMPOUNDS | |
| ATE296641T1 (en) | ORAL FORMULATION FOR ADMINISTRATION INTO THE ILLEUM CONTAINING AN ILLEUM BALE ACID TRANSPORT INHIBITOR | |
| RU2008111710A (en) | COMPOSITION FOR EMERGENCY DELIVERY OF MEDICINES | |
| WO2001068096A2 (en) | Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders | |
| CO5280060A1 (en) | BICYCLE AMINO ACIDS AS PHARMACEUTICAL AGENTS | |
| GEP20002013B (en) | Therapeutical Means | |
| ATE297728T1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING DIPEPTIDYLPEPTIDASE IV INHIBITORS TO PROMOTE GROWTH | |
| BR9407749A (en) | Process acid derivatives for their preparation and pharmaceutical compositions | |
| EP2036558A3 (en) | Orally administrable opioid formulations having extended duration of effect | |
| AU2681300A (en) | Solid oral dosage form containing an enhancer | |
| PT991646E (en) | ITRACONAZOLE WITH IMPROVED SOLUBILITY METHOD FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION THAT CONTAINS IT | |
| CA2577740A1 (en) | Method of enhancing absorptions of transmucosal administration formulations | |
| AU7239996A (en) | Inhibition of tumor necrosis factor alpha | |
| RU93055870A (en) | BIPHENYL DERIVATIVES, THE METHOD FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF HYPERTENSION AND HEART DISEASES | |
| CO5420196A1 (en) | INHIBITING COMPOUNDS OF METALOPROTEASE BIDENTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND METHODS FOR USE | |
| CO5150233A1 (en) | CONTROLLED RELEASE FORMULATION TO ADMINISTER A PDE4 INHIBITOR | |
| RU2011108587A (en) | NEW METHYLENEDIOXYPHENOL COMPOUNDS AND THEIR APPLICATION FOR TREATMENT OF DISEASES | |
| NZ252132A (en) | Rectal medicaments containing a 5ht1 receptor agonist (eg certain indole-5-sulphonamide derivatives) and a hard fat base carrier with a hydroxyl value > 15 | |
| EA200100581A1 (en) | COMBINATION OF ANALGETIC MEDICINES | |
| AR039162A1 (en) | VENLAFAXINA FORMULATIONS OF EXTENDED LIBERATION |